Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03511664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
Study identification
- NCT ID
- NCT03511664
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 861 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2018 (Actual)
- Primary completion
- Jan 27, 2021 (Actual)
- Completion
- Dec 14, 2023 (Actual)
- Last update posted
- Jan 13, 2025
2018 – 2023
United States locations
- U.S. sites
- 45
- U.S. states
- 29
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85719-1454 | — |
| VA Greater Los Angeles Healthcare System | Los Angeles | California | 90073 | — |
| University of California Los Angeles, Nuclear Medicine | Los Angeles | California | 90095 | — |
| Stanford Cancer Institute | Palo Alto | California | 94305 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| Washington DC VA Medical Center, Nuclear Medicine Service | Washington D.C. | District of Columbia | 20422 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Iowa City VA Medical Center | Iowa City | Iowa | 52246 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Tulane Medical Center, Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Chesapeake Urology Associates (CUA) P.A. | Towson | Maryland | 21204 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215-5450 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| VA Ann Arbor Healthcare System | Ann Arbor | Michigan | 48105 | — |
| University of Michigan Hospitals | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Saint Louis University Hospital | St Louis | Missouri | 63104 | — |
| VA St. Louis Health Care System - John Cochran | St Louis | Missouri | 63106 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110-1093 | — |
| XCancer Omaha / Urology Cancer Center | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada - Twain Office | Las Vegas | Nevada | 89169 | — |
| Regional Cancer Care Associates, Central Jersey Division | East Brunswick | New Jersey | 08816 | — |
| New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center | Albuquerque | New Mexico | 87109 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| New York Presbyterian Hospital/Weill Cornell Medical Center | New York | New York | 10065 | — |
| Duke University Medical Center, Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Greater Dayton Cancer Center | Kettering | Ohio | 45409 | — |
| Oregon Health and Science University, Nuclear Medicine | Portland | Oregon | 97239-3098 | — |
| Pennsylvania Cancer Specialists & Research Institute | Gettysburg | Pennsylvania | 17325 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| VA North Texas Health Care System, Nuclear Medicine Service | Dallas | Texas | 75216 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Excel Diagnostics & Nuclear Oncology Center | Houston | Texas | 77042 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22903 | — |
| Swedish Cancer Institute Research | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03511664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03511664 live on ClinicalTrials.gov.